NovoCure Ltd (NVCR) stock
NVCRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/3032% below fair value
$10.71+0.02 (+0.19%)
Close on Nov 20, 2026Market cap $1.25BP/E –Yield –
NovoCure gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
NovoCure's gross profit for the twelve months ending Sep 30, 2026 was $558.67M, up 15.4% year over year. For fiscal 2025 it was $488.47M, up 4.4% from the year before. Over ten years it grew 44.3% a year on average. The highest annual figure on record is $488.47M in fiscal 2025.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $488.47M | +4.4% |
| FY2024 | Dec 31, 2024 | $468.04M | +22.8% |
| FY2023 | Dec 31, 2023 | $381.06M | -9.9% |
| FY2022 | Dec 31, 2022 | $422.97M | +0.7% |
| FY2021 | Dec 31, 2021 | $420.15M | +8.3% |
| FY2020 | Dec 31, 2020 | $387.87M | +47.6% |
| FY2019 | Dec 31, 2019 | $262.71M | +56.4% |
| FY2018 | Dec 31, 2018 | $168.02M | +38.4% |
| FY2017 | Dec 31, 2017 | $121.42M | +231.7% |
| FY2016 | Dec 31, 2016 | $36.61M | +193.4% |
| FY2015 | Dec 31, 2015 | $12.48M | +128.8% |
| FY2014 | Dec 31, 2014 | $5.45M | +63.0% |
| FY2013 | Dec 31, 2013 | $3.35M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $148.87M | +21.6% |
| Q2 FY2026 | Jun 30, 2026 | $142.48M | +21.4% |
| Q1 FY2026 | Mar 31, 2026 | $135.13M | +16.0% |
| Q4 FY2025 | Dec 31, 2025 | $132.19M | +3.4% |
| Q3 FY2025 | Sep 30, 2025 | $122.48M | +2.3% |
| Q2 FY2025 | Jun 30, 2025 | $117.33M | +1.4% |
| Q1 FY2025 | Mar 31, 2025 | $116.47M | +11.1% |
| Q4 FY2024 | Dec 31, 2024 | $127.80M | +26.2% |
| Q3 FY2024 | Sep 30, 2024 | $119.72M | +25.7% |
| Q2 FY2024 | Jun 30, 2024 | $115.70M | +25.7% |
| Q1 FY2024 | Mar 31, 2024 | $104.81M | +13.2% |
| Q4 FY2023 | Dec 31, 2023 | $101.23M | +1.7% |
| Q3 FY2023 | Sep 30, 2023 | $95.23M | -5.9% |
| Q2 FY2023 | Jun 30, 2023 | $92.03M | -18.1% |
| Q1 FY2023 | Mar 31, 2023 | $92.57M | -15.7% |
| Q4 FY2022 | Dec 31, 2022 | $99.54M | -3.8% |
| Q3 FY2022 | Sep 30, 2022 | $101.25M | -2.1% |
| Q2 FY2022 | Jun 30, 2022 | $112.36M | +7.1% |
| Q1 FY2022 | Mar 31, 2022 | $109.82M | +1.4% |
| Q4 FY2021 | Dec 31, 2021 | $103.53M | -10.6% |
| Q3 FY2021 | Sep 30, 2021 | $103.40M | -0.8% |
| Q2 FY2021 | Jun 30, 2021 | $104.92M | +16.0% |
| Q1 FY2021 | Mar 31, 2021 | $108.31M | +40.1% |
| Q4 FY2020 | Dec 31, 2020 | $115.82M | +55.6% |
| Q3 FY2020 | Sep 30, 2020 | $104.27M | +50.8% |
| Q2 FY2020 | Jun 30, 2020 | $90.45M | +37.9% |
| Q1 FY2020 | Mar 31, 2020 | $77.33M | +44.6% |
| Q4 FY2019 | Dec 31, 2019 | $74.45M | +59.6% |
| Q3 FY2019 | Sep 30, 2019 | $69.16M | +51.0% |
| Q2 FY2019 | Jun 30, 2019 | $65.61M | +57.4% |
| Q1 FY2019 | Mar 31, 2019 | $53.50M | +57.9% |
| Q4 FY2018 | Dec 31, 2018 | $46.65M | +22.7% |
| Q3 FY2018 | Sep 30, 2018 | $45.81M | +31.0% |
| Q2 FY2018 | Jun 30, 2018 | $41.68M | +65.2% |
| Q1 FY2018 | Mar 31, 2018 | $33.89M | +46.0% |
| Q4 FY2017 | Dec 31, 2017 | $38.02M | +97.3% |
| Q3 FY2017 | Sep 30, 2017 | $34.96M | – |
| Q2 FY2017 | Jun 30, 2017 | $25.22M | – |
| Q1 FY2017 | Mar 31, 2017 | $23.22M | – |
| Q4 FY2016 | Dec 31, 2016 | $19.27M | – |
See a number that looks wrong?